Launching and commercializing complex therapies requires agility, specialized expertise and the ability to adapt as market conditions evolve. This POV explores how an integrated commercialization model can give biopharma teams flexible access to end-to-end or select capabilities while helping reduce cost, complexity and overall risk. Through real-world case studies, readers will learn how scalable infrastructure, experienced commercial leadership and data-driven execution can support successful launches, global expansion and continued value creation across the product life cycle.
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
